Abstract:Chronic myeloproliferative disorders are clonal hematopoietic stem cell disorders characterized by proliferation of one or more myeloid cell lineages in the bone marrow. The WHO classification describes six major groups of chronic myeloproliferative disorders, as follows: chronic myeloid leukemia, chronic neutrophilic leukemia, chronic eosinophilic leukemia, polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis. The diagnosis of chronic myeloid leukemia and certain types of chronic eosinophilic leukemia are based on the detection of fusion genes (in chronic myeloid leukemia the BCR/ABL fusion gene, and in chronic eosinophilic leukemia the FIP1L1-PDGFRalpha gene). On the other hand molecular markers for polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis were lacking, making it difficult to identify these disorders clearly. The authors investigated the incidence of the newly identified somatic point mutation V617F of the Janus-2 tyrosine kinase in patients with polycythemia vera, essential thrombocythemia and myelofibrosis. Janus-2 kinase is a cytoplasmic, non-receptor protein-tyrosine kinase with a key role in signal transduction from multiple hematopoietic growth factor receptors. The mutant protein is constitutively phosphorylated and is able to activate its downstream signaling pathways in the absence of any cytokine, thereby contributing to the pathogenesis of chronic myeloproliferative disorders. The authors investigated DNA samples from 132 patients with chronic myeloproliferative disorders. The V617F mutation was detected by allele-specific polymerase chain reaction, and the patients were genotyped by a DNA tetra-primer amplification refractory mutation system assay. Approximately 73% of polycythemia vera, 60% of essential thrombocythemia and 67% of myelofibrosis showed the JAK2 V617F mutation. Using the amplification refractory mutation system assay, the frequency of homozygotes was 17.5% in polycythemia vera, 5.4% in essential thrombocythemia and 0% in myelofibrosis. The authors established an effective polymerase chain reaction based method for the identification of JAK2 mutation in the routine oncohematologic diagnostics.

LNA PCR Detection for V617F Mutation of JAK2 in Myeloproliferative Diseases

Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in JAK2V617F, CALR, and MPL

Detection of JAK2 V617F Mutation by Real-Time PCR

Multiplex sequence-specific PCR detection for simultaneous screening of 5 types of JAK2 mutations in myeloproliferative diseases

Detection of JAK2 V617F Mutation Increases the Diagnosis of Myeloproliferative Neoplasms.

[Detection of JAK2V617F Mutation in Patients with Myeloproliferative Disorders with TaqMan-MGB Probe].

Detecting JAK2 V617F Mutation in Myeloproliferative Neoplasms by Microarray Based Digital PCR

Simultaneous Detection of JAK2 V617F Mutation and JAK2 Exon12 Mutations by Multiplex PCR and High-Resolution Melting Curve Analysis

Detection of the Jak2 Mutation in Myeloproliferative Neoplasms by Asymmetric Pcr with Unlabeled Probe and High-Resolution Melt Analysis

[JAK2V617F Mutation in the Patients with Myeloproliferative Disorder and Its Relation with Clinical Characteristics].

[Incidence of JAK2V617F Mutation in Myeloproliferative Diseases and Its Clinical Significance].

A Quantitative Assay for JAK2 Mutation in 135 Patients with Chronic Myeloproliferative Neoplasms

The Clinic Study of JAK2V617F Mutation Detection in Diagnosis of Polycythemia Vera

Analysis for mutational status and relative quantitation of JAK2V617F——The detection result of JAK2V617F mutation in 123 patients with chronic myeloproliferative disorders.

Clinical Analysis of JAK2 V617F Gene Mutation in 120 Patients with Myeloproliferative Neoplasms

[Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation]

JAK2 V617F Mutation in BCR-ABL Negative Patients with Myeloproliferative Disorder and Its Clinic Significance

Expression of JAK2V617F and MPLWSI5L/K mutation in 30 suspected cases of early myeloproliferarive disorders

Development And Inter-Laboratory Validation Of Unlabeled Probe Melting Curve Analysis For Detection Of Jak2 V617f Mutation In Polycythemia Vera

Detection of JAK2 mutations in paraffin marrow biopsies by high resolution melting analysis: identification of L611S alone and in cis with V617F in polycythemia vera

Development and Validation of a Tetra-Primer Amplification Refractory Mutation System-Polymerase Chain Reaction Combined with Melting Analysis-Assay for Clinical JAK2 V617F Mutation Detection